Moreover, the USP2 inhibitor ML364 exhibited the capability to enhance ErbB2 ubiquitination and accelerate its turnover, thus inhibiting the growth of ErbB2-positive breast cancer [12]. Here, ERBB2 is linked to breast cancer.